avapritinib
blueprint medicines
['#mpn', 'avapritinib', 'explorer', 'mpnsm']
presented at #ash21: in the phase 1 explorer trial, avapritinib, a selective kit inhibitor, was generally well tolerated and elicited durable clinical and molecular responses in patients with advanced systemic #mastocytosis #mpnsm #ash22 
Nature Medicine is a research journal devoted to publishing the latest advances in translational and clinical research for scientists and physicians.